Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 73

Similar articles for PubMed (Select 20824474)

1.

Systems biology approaches to the study of cardiovascular drugs.

Nikolsky Y, Kleemann R.

Methods Mol Biol. 2010;662:221-43. doi: 10.1007/978-1-60761-800-3_11.

PMID:
20824474
2.

A systems biology strategy for predicting similarities and differences of drug effects: evidence for drug-specific modulation of inflammation in atherosclerosis.

Kleemann R, Bureeva S, Perlina A, Kaput J, Verschuren L, Wielinga PY, Hurt-Camejo E, Nikolsky Y, van Ommen B, Kooistra T.

BMC Syst Biol. 2011 Aug 12;5:125. doi: 10.1186/1752-0509-5-125.

3.

Synthetic LXR agonist inhibits the development of atherosclerosis in New Zealand White rabbits.

Honzumi S, Shima A, Hiroshima A, Koieyama T, Terasaka N.

Biochim Biophys Acta. 2011 Dec;1811(12):1136-45. doi: 10.1016/j.bbalip.2011.08.009. Epub 2011 Aug 19.

PMID:
21875689
4.

Liver X receptor agonist treatment regulates inflammatory response after spinal cord trauma.

Paterniti I, Genovese T, Mazzon E, Crisafulli C, Di Paola R, Galuppo M, Bramanti P, Cuzzocrea S.

J Neurochem. 2010 Feb;112(3):611-24. doi: 10.1111/j.1471-4159.2009.06471.x. Epub 2009 Nov 4.

PMID:
19891733
5.

Fetal liver X receptor activation acutely induces lipogenesis but does not affect plasma lipid response to a high-fat diet in adult mice.

van Straten EM, van Meer H, Huijkman NC, van Dijk TH, Baller JF, Verkade HJ, Kuipers F, Plösch T.

Am J Physiol Endocrinol Metab. 2009 Nov;297(5):E1171-8. doi: 10.1152/ajpendo.00021.2009. Epub 2009 Sep 1.

6.

Liver X receptor agonist treatment reduced splanchnic ischemia and reperfusion injury.

Crisafulli C, Di Paola R, Mazzon E, Paterniti I, Galuppo M, Genovese T, Bramanti P, Cappellani A, Cuzzocrea S.

J Leukoc Biol. 2010 Feb;87(2):309-21. doi: 10.1189/jlb.0609438. Epub 2009 Dec 22.

7.

LXR agonist suppresses atherosclerotic lesion growth and promotes lesion regression in apoE*3Leiden mice: time course and mechanisms.

Verschuren L, de Vries-van der Weij J, Zadelaar S, Kleemann R, Kooistra T.

J Lipid Res. 2009 Feb;50(2):301-11. doi: 10.1194/jlr.M800374-JLR200. Epub 2008 Aug 30.

8.

Systems biology approaches and tools for analysis of interactomes and multi-target drugs.

Schrattenholz A, Groebe K, Soskic V.

Methods Mol Biol. 2010;662:29-58. doi: 10.1007/978-1-60761-800-3_2. Review.

PMID:
20824465
9.

Evaluation of anti-atherosclerotic activities of PPAR-α, PPAR-γ, and LXR agonists in hyperlipidemic atherosclerosis-susceptible F(1)B hamsters.

Srivastava RA.

Atherosclerosis. 2011 Jan;214(1):86-93. doi: 10.1016/j.atherosclerosis.2010.10.033. Epub 2010 Nov 2.

PMID:
21093860
10.

Anti-inflammatory drugs and atherosclerosis.

Moubayed SP, Heinonen TM, Tardif JC.

Curr Opin Lipidol. 2007 Dec;18(6):638-44. Review.

PMID:
17993809
11.

Liver X receptor alpha (LXRalpha) as a therapeutic target in chronic lymphocytic leukemia (CLL).

Christopherson KW 2nd, Landay A.

J Leukoc Biol. 2009 Nov;86(5):1019-21. doi: 10.1189/jlb.0509295. No abstract available.

12.

Drug discovery in a multidimensional world: systems, patterns, and networks.

Dudley JT, Schadt E, Sirota M, Butte AJ, Ashley E.

J Cardiovasc Transl Res. 2010 Oct;3(5):438-47. doi: 10.1007/s12265-010-9214-6. Epub 2010 Jul 31.

PMID:
20677029
13.

An agonist of liver X receptor slows valvular disease in a hypercholesterolemia mouse model.

Wang H, Goland S, Burton K, Czer LS, Schwarz ER, Trento A.

J Heart Valve Dis. 2010 Sep;19(5):653-64.

PMID:
21053746
14.

Systems biology approaches and pathway tools for investigating cardiovascular disease.

Wheelock CE, Wheelock AM, Kawashima S, Diez D, Kanehisa M, van Erk M, Kleemann R, Haeggström JZ, Goto S.

Mol Biosyst. 2009 Jun;5(6):588-602. doi: 10.1039/b902356a. Epub 2009 Apr 27. Review.

PMID:
19462016
15.

Diet-dependent cardiovascular lipid metabolism controlled by hepatic LXRalpha.

Lehrke M, Lebherz C, Millington SC, Guan HP, Millar J, Rader DJ, Wilson JM, Lazar MA.

Cell Metab. 2005 May;1(5):297-308.

16.

Atherosclerosis and liver inflammation induced by increased dietary cholesterol intake: a combined transcriptomics and metabolomics analysis.

Kleemann R, Verschuren L, van Erk MJ, Nikolsky Y, Cnubben NH, Verheij ER, Smilde AK, Hendriks HF, Zadelaar S, Smith GJ, Kaznacheev V, Nikolskaya T, Melnikov A, Hurt-Camejo E, van der Greef J, van Ommen B, Kooistra T.

Genome Biol. 2007;8(9):R200.

17.

Activation of LXRα induces lipogenesis in HaCaT cells.

Hong I, Rho HS, Kim DH, Lee MO.

Arch Pharm Res. 2010 Sep;33(9):1443-9. doi: 10.1007/s12272-010-0919-5. Epub 2010 Oct 14.

PMID:
20945144
18.

Non-steroidal LXR agonists; an emerging therapeutic strategy for the treatment of atherosclerosis.

Bennett DJ, Cooke AJ, Edwards AS.

Recent Pat Cardiovasc Drug Discov. 2006 Jan;1(1):21-46. Review.

PMID:
18221072
19.

Activation of liver X receptors with T0901317 attenuates cardiac hypertrophy in vivo.

Kuipers I, Li J, Vreeswijk-Baudoin I, Koster J, van der Harst P, Silljé HH, Kuipers F, van Veldhuisen DJ, van Gilst WH, de Boer RA.

Eur J Heart Fail. 2010 Oct;12(10):1042-50. doi: 10.1093/eurjhf/hfq109. Epub 2010 Jun 29.

PMID:
20587624
20.

Rosuvastatin displays anti-atherothrombotic and anti-inflammatory properties in apoE-deficient mice.

Monetti M, Canavesi M, Camera M, Parente R, Paoletti R, Tremoli E, Corsini A, Bellosta S.

Pharmacol Res. 2007 May;55(5):441-9. Epub 2007 Feb 12.

PMID:
17350858
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk